Zymeworks Announces Participation in Upcoming Investor Conferences
January 31 2024 - 6:00AM
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology
company developing a diverse pipeline of novel, multifunctional
biotherapeutics to improve the standard of care for
difficult-to-treat diseases, today announced that management will
participate in the following upcoming investor conferences:
- Guggenheim Healthcare Talks 6th Annual Biotechnology
Conference: Zymeworks’ management will participate in one-on-one
meetings and a fireside chat on February 8th at 2:30 pm Eastern
Time (ET) in New York, NY.
- Oppenheimer 34th Annual Healthcare Life Sciences Conference:
Zymeworks’ management will participate in virtual one-on-one
meetings and present on February 13th at 9:20 am ET.
- Citi's 2024 Virtual Oncology Leadership Summit: Zymeworks’
management will participate in a fireside chat on February 22nd at
8:00 am Pacific Time (PT).
All presentations and webcasts will be available on Zymeworks’
website at http://ir.zymeworks.com/events-and-presentations.
About Zymeworks Inc.
Zymeworks is a global biotechnology company committed to the
discovery, development, and commercialization of novel,
multifunctional biotherapeutics. Zymeworks’ mission is to make a
meaningful difference in the lives of people impacted by
difficult-to-treat cancers and other diseases. The Company’s
complementary therapeutic platforms and fully integrated drug
development engine provide the flexibility and compatibility to
precisely engineer and develop highly differentiated antibody-based
therapeutic candidates. Zymeworks engineered and developed
zanidatamab, a HER2-targeted bispecific antibody using the
Company’s proprietary Azymetric™ technology. Zymeworks has entered
into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz
Pharmaceuticals Ireland Limited (Jazz), granting each exclusive
rights to develop and commercialize zanidatamab in different
territories. Zanidatamab is currently being evaluated in multiple
global clinical trials as a potential best-in-class treatment for
patients with HER2-expressing cancers. Zymeworks is rapidly
advancing a deep pipeline of product candidates based on its
experience and capabilities in both antibody drug conjugates and
multispecific antibody therapeutics across multiple novel targets
in indications that represent areas of significant unmet medical
need. In addition to Zymeworks’ wholly owned pipeline, its
therapeutic platforms have been further leveraged through strategic
partnerships with global biopharmaceutical companies. For
information about Zymeworks, visit www.zymeworks.com and follow
@ZymeworksInc on X.
Contacts:
Investor Inquiries:
Shrinal InamdarDirector, Investor Relations(604)
678-1388ir@zymeworks.com
Media Inquiries:
Diana PapoveSenior Director, Corporate Communications(604)
678-1388media@zymeworks.com
Zymeworks (NASDAQ:ZYME)
Historical Stock Chart
From Jun 2024 to Jul 2024
Zymeworks (NASDAQ:ZYME)
Historical Stock Chart
From Jul 2023 to Jul 2024